Ibrahim Aldoss, MD

Ibrahim Aldoss, MD, is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope

Articles

Highlighting Key ALL Updates and Data From EHA 2025

September 8th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss key data in acute lymphoblastic leukemia presented at the 2025 EHA Congress.

Early Data for Subcutaneous Blinatumomab in R/R ALL

September 8th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss data for subcutaneous in relapsed/refractory acute lymphoblastic leukemia.

Dr Aldoss on MRD Negativity Outcomes With Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

September 3rd 2025

Ibrahim T. Aldoss, MD, discusses MRD negativity outcomes with ponatinib vs imatinib in newly diagnosed Philadelphia chromosome–positive ALL.

Blinatumomab Consolidation in Younger Adult BCR:ABL1–Negative B-ALL

September 2nd 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab consolidation in BCR:ABL1–negative B-ALL.

Adding Blinatumomab to the CALGB 10403 Regimen in B-Cell Precursor ALL in MRD-Negative Remission

September 2nd 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the addition of blinatumomab to the CALGB 10403 regimen in MRD-negative acute lymphoblastic leukemia.

Defining the Role of Blinatumomab in Acute Lymphoblastic Leukemia

August 25th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab in acute lymphoblastic leukemia management.

Current First-Line Treatment Considerations in Acute Lymphoblastic Leukemia

August 25th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss first-line treatment options for acute lymphoblastic leukemia.

Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

March 20th 2025

Drs Aldoss and Jabbour discuss an analysis of PhALLCON that support the use of ponatinib monotherapy after TKI/chemotherapy treatment in Ph-positive ALL.

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Current Standards of Care for Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss current standards of care for the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Prevalence and Prognosis of Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr Aldoss on Responses With WU-CART-007 After Enhanced Lymphodepletion in R/R T-ALL/LBL

June 14th 2024

Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.

Dr Aldoss on the Utility of Ponatinib in Ph+ ALL

May 6th 2024

Ibrahim Aldoss, MD, discusses the utility of ponatinib in the phase 3 PhALLCON trial for patients with newly diagnosed, Ph+ acute lymphoblastic leukemia.

Dr Aldoss on the Mechanism of Action of Ponatinib in Ph+ ALL

April 29th 2024

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.

Dr Aldoss on the Use of Revumenib in KMT2A-Rearranged Acute Leukemia

January 26th 2024

Ibrahim T. Aldoss, MD, discusses the use of revumenib monotherapy in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements.

Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALL

July 12th 2023

With their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.

Notable Advancements in Treatment for ALL

July 12th 2023

Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.